

Resource Summary Report

Generated by [dkNET](#) on Aug 25, 2026

EL4

RRID:CVCL_0255

Type: Cell Line

Proper Citation

RCB Cat# RCB1641, RRID:CVCL_0255

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0255

Proper Citation: RCB Cat# RCB1641, RRID:CVCL_0255

Description: Cell line EL4 is a Cancer cell line with a species of origin *Mus musculus* (Mouse)

Sex: Sex unspecified

Disease: Mouse precursor T cell lymphoblastic lymphoma/leukemia

Defining Citation: [PMID:4099030](#), [PMID:4867923](#), [PMID:14801344](#), [PMID:30084848](#)

Comments: Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981).

Category: Cancer cell line

Organism: *Mus musculus* (Mouse)

Name: EL4

Synonyms: EL-4, EL 4, E.L.4

Cross References: BTO:BTO_0003432, CLO:CLO_0002913, CLO:CLO_0050166, EFO:EFO_0022736, MCCL:MCC:0000146, CLDB:cl1158, CLDB:cl1159, CLDB:cl1160, ATCC:TIB-39, BCRC:60179, CCRID:1101MOU-PUMC000136, CCRID:3101MOUTCM41, CCRID:4201MOU-CCTCC00136, CCTCC:GDC0136, ChEMBL-Cells:ChEMBL3308380, ChEMBL-Targets:ChEMBL614293, CLS:300653, DSMZ:ACC-831, DSMZCellDive:ACC-831, ECACC:85023105, JCRB:IFO50027, JCRB:JCRB1350, KCB:KCB 2013027YJ, KCLB:40039, Lonza:760, NCBI_Iran:C114, PRIDE:PXD008733, PubChem_Cell_line:CVCL_0255, RCB:RCB1641, TKG:TKG 0150, Wikidata:Q54832230

ID: CVCL_0255

Vendor: RCB

Catalog Number: RCB1641

Record Creation Time: 20220427T215832+0000

Record Last Update: 20260815T232736+0000

Ratings and Alerts

No rating or validation information has been found for EL4.

Warning: Discontinued: JCRB; IFO50027

Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981).

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 435 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Zhao Y, et al. (2026) Combined Photothermal and mTOR-Targeted Therapy Overcomes Immune Evasion and Enhances Checkpoint Blockade Efficacy in Metastatic Triple-Negative Breast Cancer. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), 13(10), e13711.

Yoshida Y, et al. (2026) PD-1 suppresses CAR signaling by forming the inhibitory signalosome colocalizing to CAR microclusters. *Communications biology*, 9(1), 135.

Beke F, et al. (2026) L-type voltage-gated Ca²⁺ channels control T cell killing via non-canonical Hedgehog signalling. *EMBO reports*, 27(13), 3689.

Philbrook P, et al. (2026) Medium-Chain Fatty Acid Receptor GPR84 Modulates Cytotoxic CD8 T-cell Antitumor Immunity through Metabolic Reprogramming. *Cancer immunology research*, 14(4), 640.

Tang A, et al. (2026) Targeting BCMA in multiple myeloma with a trifunctional NK cell engager. *Cell reports. Medicine*, 7(3), 102628.

Fischer TD, et al. (2026) Intratumoral Virus-Like Particles Containing a TLR9 Agonist Combined with Systemic ?PD-1 Activate Tumor-Specific CD8+ T Cells. *Cancer research communications*, 6(5), 1006.

Kim B, et al. (2026) Selective Targeting of Tip Endothelial Cells as a Therapeutic Strategy for Tumor Angiogenesis. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), 13(18), e12975.

Georgievski A, et al. (2026) Valrubicin-loaded immunoliposomes targeting antigens on immunosuppressive cells to circumvent resistance to cancer immunotherapy. *Cell reports. Medicine*, 7(3), 102632.

Miller ML, et al. (2026) Fungal-derived cellobiose metabolic pathway fuels T cells to bypass intratumoral glucose competition. *Cell*, 189(6), 1717.

Gu H, et al. (2026) FAP⁺ Macrophages Orchestrate Immune Evasion in Multiple Myeloma by Dual Regulation of PD-L1 and T Cell Senescence. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), 13(18), e06239.

Van Le T, et al. (2026) Cooperative IFN- γ and TLR9 signaling reprogram tumor-associated macrophages to enhance antitumor immunity in melanoma. *Biochemical and biophysical research communications*, 831, 154245.

Gao Y, et al. (2025) T cell cholesterol transport links intestinal immune responses to dietary lipid absorption. *Science (New York, N.Y.)*, 390(6769), eadt4169.

Kojima Y, et al. (2025) The antipsychotic drug thiothixene stimulates macrophages to clear pathogenic cells by inducing arginase 1 and continual efferocytosis. *Science signaling*, 18(881), eads6584.

Phelps CM, et al. (2025) Exercise-induced microbiota metabolite enhances CD8 T cell antitumor immunity promoting immunotherapy efficacy. *Cell*.

Yang M, et al. (2025) Targeting lipid scrambling potentiates ferroptosis and triggers tumor immune rejection. *Science advances*, 11(33), eadx6587.

Chowdhury IH, et al. (2025) PARP1-NFATc1-PD1 pathway of maturation and stability of CD8⁺T cells is beneficial against chronic *Trypanosoma cruzi* infection. *iScience*, 28(7), 112926.

Clark ML, et al. (2025) Mitochondrial complex IV remodeling in tumor-associated macrophages amplifies interferon signaling and promotes anti-tumor immunity. *Immunity*, 58(7), 1670.

Tomaz da Silva M, et al. (2025) The TWEAK/Fn14 signaling mediates skeletal muscle wasting during cancer cachexia. *iScience*, 28(7), 112714.

Kaika A, et al. (2025) Early Detection of Cell Death Using Transmembrane Water Exchange Magnetic Resonance Imaging. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), e13317.

Fan AE, et al. (2025) STAT5 Activation Enhances Adoptive Therapy Combined with Peptide Vaccination by Preventing PD-1 Inhibition. *Molecular cancer therapeutics*, 24(3), 419.